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Abstract: Personalized medicine (PM) or precision medicine has been defined as an innovative 
approach that takes into account individual differences in people’s genes, environments, and 
lifestyles in prevention and treatment of disease. In PM, genomic information may contribute 
to the molecular understanding of disease, to optimize preventive health care strategies, and to 
fit the best drug therapies to the patient’s individual characteristics. Evidence development in 
the era of genomic medicine is extremely challenging due to a number of factors. These include 
the rapid technological innovation in molecular diagnostics and targeted drug discoveries, and 
hence the large number of mutations and multiple ways these may influence treatment decisions. 
Although the evidence base for PM is evolving rapidly, the main question to be explored in this 
article is whether existing evidence is also fit for comparative effectiveness research (CER). As 
a starting point, this paper therefore reflects on the evidence required for CER and the evidence 
gaps preventing decisions on market access and coverage. The paper then discusses challenges 
and potential barriers for applying a CER paradigm to PM, identifies common methodologies 
for designing clinical trials in PM, discusses various approaches for analyzing clinical trials 
to infer from population to individual level, and presents an example of a clinical trial in PM 
(The RxPONDER TRIAL) demonstrating good practice. The paper concludes with a future 
perspective, including modeling approaches for evidence synthesis.
Keywords: personalized medicine, precision medicine, comparative effectiveness research, 
health technology assessment, oncology, genomics
Introduction
The US Institute of Medicine defines comparative effectiveness research (CER) as the 
generation and synthesis of evidence that compares the benefits and harms of alternative 
methods for preventing, diagnosing, treating, and/or monitoring clinical conditions, or 
for improving the delivery of care. The purpose of CER is to assist consumers, clini-
cians, purchasers, and policy makers to make informed decisions that will improve 
health care at both the individual and population levels.1
While CER has emerged in the USA, the European Union has less strictly called for 
CER as a new paradigm, partly because of the rigorous health technology assessment 
(HTA) processes that exist in many European Union countries. A central tenet of HTA 
is the use of pragmatic clinical trials to assess at least two interventions used in clinical 
practice. European Guidelines in HTA suggest that two or more existing strategies 
should be compared under real-life circumstances in order to produce meaningful and 
scientific legitimate (or evidence-based) decision support.
Several authors have discussed the challenges of applying CER to the field of 
personalized or precision medicine.2–6 Personalized medicine (PM), recently also 
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introduced as “precision medicine” refers to the change from 
a “one-size-fits-all” approach, to getting the “right treatment 
for the right individual”. The genomic information may 
concern the patient’s inherited DNA (germline) or changes 
to DNA that have occurred over time that are not heritable, 
including those changes that result in malignancies (somatic 
DNA and changes). This is particularly true in oncology, 
where medicines are being developed to target specific muta-
tions found in patients’ tumors. One of the most important 
developments in PM is genome sequencing, leading to dra-
matically lower costs and increased speeds of characterizing 
tumor DNA. This revolution is – despite many clinical and 
technical hurdles – facilitating this change.7
The evidence base for PM is evolving rapidly, but the 
question for this article is whether the evidence being 
generated fits the requirements in CER. The focus in this 
paper is oncology, arguably the area with the most activity 
in genomically-targeted treatment. We posit that for oncol-
ogy the evidence base generally does not fit an ideal for 
CER. Yet, if CER could demonstrate improved effective-
ness of PM at the individual level or in subpopulations in 
the future, it may stimulate the development of products 
that are narrowly targeted to patients with specific genetic 
or other  characteristics.8 In this way, PM can contribute to 
better customized care, with better health outcomes for the 
individual at a lower cost for society because less people will 
receive ineffective drug treatment.
This paper starts with a discussion about the specifics of 
CER in PM by reviewing the literature and identifying known 
evidence gaps. Second, several issues for developing clinical 
trials for PM are discussed while specifically looking into 
some specific design challenges and statistical methods to infer 
from the population to the individual level. As an example, a 
trial was designed for PM application and was introduced as 
a best practice. Finally, a future perspective is offered identi-
fying some recent methodological progress generating better 
information on the comparative effectiveness of genomically-
targeted therapies relative to other accepted cancer care.
From personalized and precision 
medicine to personalized health 
care
While the terms PM and precision medicine are adopted by 
large clinical and research communities, its definition is still 
vague and subject to controversy. This is mainly (or partly) 
due to the fact that PM can be observed from different points 
of view. The following two definitions illustrate the issue. 
Schleidgen et al (re)define PM as: “to improve stratification 
and timing of health care by utilizing biological information 
and biomarkers on the level of molecular disease pathways, 
genetics, proteomics as well as metabolomics”.9 The Obama 
administration defines PM as “[…] an innovative approach 
to disease prevention and treatment that takes into account 
individual differences in people’s genes, environments, 
and lifestyles” (https://www.whitehouse.gov/the-press-
office/2015/01/30/fact-sheet-president-obama-s-precision-
medicine-initiative). These different points of view have led 
to some discussion whether the term “precision” medicine 
indeed is different from PM.10
What is even more interesting, though, is that a large 
group of people prefer the term “personalized health care” to 
make explicit that there is a general trend of tailoring health 
care to the specific needs of patients. In personalized health 
care, managing patient heterogeneity in terms of their biology, 
values and preferences is important. Stratification of patients 
based on molecular profile alone would be sub optimal, given 
differences in clinical characteristics, patients’ preferences 
and values which affect the effectiveness of treatment.11 The 
personalization of health care should therefore be seen as an 
integrated whole, tailoring health care to individual patients.
Personalized health care and CER
To inform regulatory agencies about approval of new phar-
maceuticals, three relevant developments have emerged over 
the past decade, including evidence-based medicine, CER, 
and HTA. In their insightful overview, Luce et al contrast 
CER, evidence-based medicine, and HTA.12 Although there 
are many similarities, a main difference is that HTA tradition-
ally takes the costs into the equation and more specifically 
informs reimbursement decisions.12 However, both CER 
and HTA aim to inform decision makers about whether an 
intervention will work in practice (Figure 1).
The introduction of CER has led to an intense discussion 
amongst academics and policy makers, since CER and HTA 
both analyze the effectiveness of medical treatment, with the 
intent of informing clinical decisions and policies affecting 
health care.5 The common methodological framework in CER 
is the randomized controlled trial (RCT), although several 
other clinical research strategies may be used.13,14 While 
comparison of two or more drugs at the same time is essen-
tial for CER, the US Food and Drug Administration (FDA) 
enabling law (FDC Act, as amended in 1962) does not require 
assessment of comparative effectiveness for  decision support. 
Furthermore, the US legislative history made it very clear 
there was no requirement to determine relative effectiveness. 
A new drug does not have to be better than, or even as good 
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Figure 1 Comparison of comparative effectiveness research, evidence-based medicine, and health technology assessment.
Note: Adapted from Luce et al. Copyright © 2010 Milbank Memorial Fund. Published by Wiley Periodicals inc. Luce BR, Drummond M, Jönsson B, et al. EBM, HtA, and CER: 
clearing the confusion. Milbank Q. 2010;88(2):256–276.12
Abbreviation: RCt, randomized controlled trial.
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as, existing treatment to be approved by the FDA. This is 
similar to the European Medicines Agency regarding their 
market authorization process, which basically evaluates the 
therapeutic safety and harm of a new drug.
Several papers have been published discussing the chal-
lenges in evidence development for PM. Conti et al identified 
five major challenges that need to be overcome while trans-
lating the promise of genomics into PM, based on a panel 
discussion with experts.3 Most of these are related to issues as 
discussed in CER, including: 1) the limited quantity and qual-
ity of available evidence of effectiveness, 2) the complexity of 
information provided by currently available tests (for success, 
many genes should be linked to many diseases), 3) the rapid 
commercialization of new genetic tests with limited oversight 
or regulation of genetic testing, 4) apprehension of genomics 
by physicians, patients, and payers, and 5) the uncertainty about 
clinical utility. With regard to the latter, many other experts 
agree that clinical utility – the impact of the PM test on patient 
outcomes – is more important15 and should drive CER.16,17
While these five issues are generally acknowledged, many 
experts have argued that, while evidence development in 
theory is not different, there are several other barriers that 
impede the translation of PM to clinical practice.
One such barrier, preventing evidence development of 
PM, is pointed out by Towse and Garrison. They argued 
that there is generally a disincentive for manufacturers to 
generate the evidence for molecular tests, as more detailed 
information about biomarkers will reduce the target popu-
lation size for a drug and thus will decrease the returns for 
industry.18 The complexity of getting the incentives right, 
for translating PM to the clinic, requires the involvement of 
stakeholders to examine unexpected implementation prob-
lems and to better design CER to inform decision-making, 
supporting the argument of a multiple stakeholder approach 
in designing CER.19
Similar with the notion of the importance of clinical 
utility, another discussion arises, ie, how to determine value. 
In this respect, the choice for a clinical end point in clini-
cal trials is far from trivial. CER aims to inform clinicians, 
patients, and policy makers about the value of diagnostic 
tests, and PM may be quite different to these stakeholders. 
Phillips et al pointed out that for effective translation to the 
market, a systematic analysis of utilization, patient prefer-
ences, and economic value is required.20 Although this paper 
is not specifically about the economic value of PM, we pose 
measuring patient preferences to measure value in addition 
to clinical outcomes to be important.21 Typically, discrete-
choice experiments or multi-criteria decision analysis are 
used to quantify stakeholder weights for clinical outcomes 
and process of care.22,23
Consequences for trial design and 
analysis in PM
One of the biggest challenges to PM is that RCTs are 
designed to draw conclusions at the population level, 
where PM specifically is interested in the individual level. 
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The complexity arises because trials cannot be designed for 
a specific subgroup, as these groups may not be known a 
priori. And if those subgroups would be identified a priori, 
treatments are selected based on the presence or absence of 
molecular markers and thus additional diagnostic tests.
I-Spy was one of the first unique trials dealing with the 
complex issues of designing RCTs allowing treatment selec-
tion based on specific marker expressions.24,25 In general, 
three challenges related to RCT design in PM are discussed 
here: 1) including identifying and handling of multiple sub-
groups, 2) complexity of mutations and tumor biology and 
3) statistical approaches to analyze data at the individual 
level.
the large number of biomarkers creates 
a large quantity of subgroups
In the first place, it is not possible to design RCTs for sub-
groups that are unknown at the design stage. RCTs need 
to be certain about which markers to target.26 Companion 
diagnostic tests are expected to identify potential responders, 
but it is hard to do a trial comparing potential responders to 
nonresponders. Such a trial needs to be designed smart, and 
requires many patients to avoid low statistical power. As 
treatment is based on the presence or absence of a particular 
mutation, it is hard to design controlled trials randomizing 
patients with all different and unique combinations of muta-
tions. Such trials are only possible in case of either a single or 
small number of mutations. However, with the availability of 
whole genome sequencing in clinical patient care, the amount 
of information that will become available is extremely com-
plex to handle in RCTs.
Genetic mutations are less tumor specific, 
and expressions are dynamic and 
can differ between early cancer and 
metastatic disease
The information provided by sequencing, combined with the 
growing literature cataloging how these disruptions affect the 
biological function of the cancer cells across tumor types, is 
hinting at a future where cancer therapy will be defined not 
only by the site of the cancer (eg, breast or lung) but also 
by matching the patient’s aberrant genomic morphology to 
one or more drugs that have been shown to be effective in 
targeting those disruptions in those tumors. A roadmap has 
been published outlining the process by which oncology will 
move from the current model of patients being managed 
through well-defined and referenced therapy “pathways” to 
highly variable individualized combinations of treatments 
that are based on a genomic signature specific to the patient’s 
tumor.
Part of this is the growing evidence base that genomic 
expressions are dynamic over time and differ between early 
stage tumors and metastatic disease.27,28 Many biologicals 
are being developed targeting the same molecular mecha-
nism, yet the expressions may change over time making the 
drug less or more effective.29 For clinical trial design, such 
dynamic behavior is hard to control for and potentially may 
lead to misclassification affecting the power of the study. In 
addition to these considerations, there is a need for further 
research on the identification and interpretation of response 
markers for clinical decision-making. For instance, circu-
lating tumor cells or cell-free DNA may be considered as 
markers of treatment response, to guide switching therapies.30 
Currently, clinical trials are being prepared investigating the 
use of such markers in addition to clinical examination and 
imaging biomarkers (studies on switching from first-line 
[docetaxel] to second-line [cabazitaxel] chemotherapy in 
metastatic castration-resistant prostate cancer in the USA 
[clinicaltrials.gov: NCT01718353] and the CTC-Stop trial 
in the UK are led by Prof Johann de Bono at Institute for 
Cancer Research, London).
statistical approaches to infer from the 
population to the individual
One specific problem in the analysis of RCT data for PM 
has to do with moving away from population mean treatment 
effect to focus on subgroup – or even individual-level treat-
ment effect. Several statistical approaches can be identified in 
this respect; however, the statistical analysis of RCT data to 
derive PM recommendations requires careful considerations. 
Before starting with the analysis, researchers need to consider 
the RCT design used that generated the data at hand; a gen-
eral principle of good practice and applied research31 valid 
both for population-average and individualized treatment 
decisions alike. Conditional on the study design, research-
ers will then need to define the analytical paradigm within 
which they intend to operate, identifying the individualized 
treatment rule (ie, a model that gives the optimal treatment 
for each patient [this is often based on Rubin’s potential out-
comes framework]);32 the (type of) predictor and prognostic 
variables to be used in the model; evaluating the performance 
of the models (in terms of goodness-of-fit and internal valida-
tion); choosing a method of inference based on the type of 
outcome variable and the data dimension; fitting the model 
to a training data set (to identify key covariates and estimate 
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model parameters) and applying the treatment rules to future 
patients (to assess the prognostic and predictive ability of 
the model and select the optimal treatment).33 In this sense, 
the trial design will be influential in determining the analyti-
cal derivation of individualized treatment rules. The above 
analytical sequence is appropriate when the individualized 
treatment rule is to take place at one time point only. A num-
ber of more general (possibly realistic) cases encompassing 
sequential treatment decisions can be imagined to take place 
in oncology, whereby, following treatment failure, patients 
and their clinicians may choose to switch drug therapy.34 
The analysis of these types of trials require not only careful 
design35 but more sophisticated dynamic treatment regimen 
analytical models,36 which take into account information 
from the patient’s past history and any other relevant factors 
(eg, treatment preferences). Finally, more recently authors 
have argued that the analysis of RCT data for PM is an evo-
lutionary process in which system biology-based in-silico 
models are developed.37 These models integrate RCT data 
and multiple complementary information from other sources 
(eg, biobanks) and constantly update with more information 
as this is generated.
The RxPONDER trial: a multi-
stakeholder perspective
From the previous sections it emerges that clinical trial design 
in PM is challenging in multiple ways. The RxPONDER38 
trial describes good practice while referring to the issues 
discussed in the section “Personalized health care and CER”, 
by: 1) overcoming the complexity of information provided 
by currently available tests (clear linkage of specific genes 
to therapy); 2) apprehension of genomics by physicians, 
patients, and payers by involving multiple stakeholders; and 
3) emphasizing the clinical utility with regard to treatment 
consequences.
The RxPONDER trial is designed to evaluate the role of 
a gene expression profile test, the 21-gene assay (Oncotype 
DX®), for women with early stage breast cancer involving the 
lymph nodes.38 Guidelines suggest that women with lymph 
node-positive breast cancer should be routinely offered 
chemotherapy but there is evidence that many patients who 
receive chemotherapy do not benefit in terms of reducing 
their risk of cancer recurrence.1 OncotypeDX® is now being 
marketed as an option for patients with hormone-receptor-
positive breast cancer involving zero to three positive nodes, 
but the test’s role among women with node-positive disease 
has not been established. Existing evidence includes retro-
spective evaluations of two randomized clinical trials finding 
that the 21-gene assay recurrence score (RS) had reasonable 
predictive value in identifying women who will benefit from 
chemotherapy with node-positive breast cancer.2,3
While reducing the use of chemotherapy in women 
who will not benefit from it could potentially spare thou-
sands from chemotherapy-related morbidity and reduce the 
related expenditures substantially, it is important to have 
high-quality evidence from a prospective clinical trial due 
to the risks of not giving chemotherapy to those who would 
otherwise benefit. Another way to describe this issue is that 
better evidence is needed to find an RS value that produces 
an acceptable level “false negative” RS. Existing retrospec-
tive data are insufficient to determine whether the RS can 
be calibrated to provide a balance that would be acceptable 
to women and providers.4
To evaluate the comparative effectiveness of management 
using OncotypeDX® versus current practice, South-West 
Oncology Group (SWOG), a large US-based cancer clinical 
trials cooperative group, in conjunction with the US National 
Cancer Institute, designed a prospective clinical trial, SWOG 
S1007 (clinical trial registry: NCT01272037), given the acro-
nym RxPONDER.38 This multicenter Phase III trial targets 
women with hormone-receptor-positive and HER2-negative 
breast cancer involving 1–3 lymph nodes. Women with a 
21-gene assay RS of 25 or less are randomized to endocrine 
therapy alone versus chemotherapy followed by endocrine 
therapy. Uniquely, the trial design phase involved active par-
ticipation of an external stakeholder group prior to finalizing 
the trial design and end points for the purpose of ensuring 
that the study results would be informative to patients, cli-
nicians, and payers while balancing considerations such as 
internal validity and trial  feasibility. Another important fea-
ture addressed the problem that reimbursement for genomic 
tests in the context of a clinical trial is unclear.
Several stakeholders identified the importance of look-
ing into patient preferences. It is known that some patients 
ignore the results of their 21-gene RS test, which potentially 
may reduce its clinical utility and thus cost-effectiveness. 
Therefore, more specific information about the patients 
will help practitioners to understand influences on patient 
decision-making in breast cancer care.
Working with the stakeholder group and many health 
insurers, a joint funding arrangement involving health 
insurers and the National Cancer Institute was created for 
the RxPONDER study. The trial began enrolling patients 
in September 2013. Table 1 lists the primary aim and study 
hypothesis, while comparative effectiveness questions for 
S1007 can be found in the original publication.38
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Table 1 Primary and secondary objectives and hypotheses for 
the RxPONDER study
Primary objective
1  to determine the effect of chemotherapy in patients with node-positive 
breast cancer who do not have high recurrence score (Rs) by Oncotype 
DX®. in patients with 1–3 positive nodes, and who have hormone 
receptor (HR)-positive and HER2-negative breast cancer with Rs 25 and 
treated with endocrine therapy, we will test whether the difference in 
disease-free survival for patients treated with chemotherapy compared 
to no chemotherapy depends directly on the magnitude of RS. If benefit 
depends on the Rs score, the trial will determine the optimal cutoff 
point for recommending chemotherapy or not.
Hypotheses
H1:  The 21-gene RS will predict the benefit of chemotherapy in 
node-positive (1–3 nodes) and HR-positive breast cancer patients 
with Rs #25 treated with state-of-the-art endocrine therapy. 
Chemotherapy benefit (if it exists) will increase as the RS increases.
H2:  Chemotherapy is not beneficial for some patients with RS in the 
range of 0–25 and the point of equivalence between chemotherapy 
and no chemotherapy can be identified in this range. Above this 
point, patients begin to benefit from the addition of chemotherapy. 
We will identify an Rs cutoff point for which there is clinically 
significant benefit of chemotherapy for all RS values above this cutoff 
point.
Note: Adapted from Contemporary Clinical trials, volume 34, issue 1, Ramsey sD, 
Barlow WE, Gonzalez-Angulo AM, et al. integrating comparative effectiveness design 
elements and endpoints into a phase iii, randomized clinical trial (sWOG s1007) 
evaluating oncotype DX-guided management for women with breast cancer involving 
lymph nodes, Pages 1–9, Copyright 2013, with permission from Elsevier.38
Abbreviations: H1, hypothesis 1; H2, hypothesis 2.
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test results, etc), often an important feature of PM. As cancer 
increasingly is considered a chronic disease, it is required to 
model entire care pathways using patient-level data. In addi-
tion, molecular diagnostics for evaluating mutations in tumor 
biology are increasingly being employed along the clinical 
care pathway as a response marker to guide switches from 
first-line to second-line chemotherapy and further. These 
dynamics require more understanding of the tumor biology, 
mechanism to capture tumor tissue and analytic capacity to 
identify treatment response, how patients’ preferences change 
over time, and to integrate these in CER.
Large observational studies and databases that contain 
extensive genomic, phenotype, socioeconomic, clinical, 
and outcomes data for thousands of patients (“big data”) are 
potentially useful additions to more commonly used health 
outcomes data collected in trials and other planned clinical 
research.40 Although planned data collection is reliable and less 
prone to all sorts of bias, it is also of limited value to evaluate 
the dynamics in the health system. In particular, observational 
studies and other big data sources would allow more detailed 
analysis of health operations, compliance to guidelines, and 
the dynamic interactions in the system, and how they impact 
patients in the context of PM. These data sources may be useful 
in addition to other registries, with an emphasis on the use of 
claims and administrative data and electronic medical records. 
Claims databases and electronic medical records provide a 
rich source of data to analyze trends in health care and health 
care  utilization. Claims and administrative data sources would 
allow evaluation of access to care, and also monitor the amount 
of physician–physician interactions as a proxy for quality of 
care evaluating the effect of care coordination programs.41 
Several computational approaches are used and explored to 
mine big data that may also apply to PM.42 But other statistical 
approaches that deal with observational data sets are promis-
ing, such as propensity scores or the instrumental variable 
approach.43 In particular, the instrumental variable approach 
is gaining popularity as a method to translate the average treat-
ment effect into a patient-level treatment effect, accounting for 
patient-level heterogeneity.44
Finally, CER intends to generalize findings from clinical 
trials to inform health policy. Resource constraints (eg, lack of 
sequencing capacity) determine utilization, and should also be 
captured in models to inform health policy. One future direc-
tion that has found its way into outcomes research is dynamic 
simulation modeling.45,46 Dynamic simulation modeling 
methods, such as discrete-event simulation and agent-based 
modeling, may be used to incorporate the complex interactions 
in to the health care delivery system, the emergent behavior 
Future perspectives
While several good practices for designing clinical trials in 
PM can be identified and presented, the ongoing  development 
and application of its precepts is dynamic. Over time, current 
evidence for development paradigms are likely to be insuf-
ficient, because they are largely based on a standardized com-
parison between two or more treatments in a well-identified 
population. These principles are challenged in PM. In this 
perspective, we pose that three methodological developments 
are required and may contribute to advancement of PM, 
which include 1) modeling approaches, 2) use of “big data”, 
and 3) resource constraints in health service delivery.
First, the target population may not be well defined, and 
the treatment strategies can be dynamic, sequential, and very 
specific for the individual. In such cases where standard 
RCTs cannot be carried out easily, simulation modeling 
approaches may be useful.39 However, standard modeling 
such as being employed in CER and HTA is not appropriate 
in PM for three distinct reasons. Standard cohort model-
ing methods, such as Markov state-transition models, may 
not be sufficient because such models have difficulties in 
accommodating time-dependent behavior (eg, the patient’s 
reaction and behaviour as a result of specific clinical events, 
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of the system, and the dynamics of diagnostic and treatment 
interactions, which are very useful in PM. In addition to such 
dynamic modeling approaches, the complexity of translating 
PM to the clinic requires an examination and involvement of 
stakeholders, supporting the argument of a multiple stake-
holder approach in designing CER.17,19
Executive summary
Evidence development in the era of genomic medicine is 
extremely challenging due to a number of factors. These 
include the rapid technological innovation in molecular 
diagnostics and targeted drug discoveries, and hence the 
large number of mutations and multiple ways these may 
influence treatment decisions. The evidence base for PM is 
evolving rapidly, but the question for this article is whether 
the  evidence being generated fits the requirements in CER.
Although several best practices can be identified, such 
as the RxPONDER trial, current evidence for development 
paradigms may be insufficient, because they are largely based 
on a standardized comparison of two or more treatments in 
a well-identified population. These principles are challenged 
in PM. In this perspective, we pose that three methodological 
developments are required and may contribute to advance-
ment of PM, which include: 1) modeling approaches, 2) use 
of big data, and 3) methods to incorporate resource and 
system constraints in health care delivery models.
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